NASDAQ:CTIC CTI BioPharma (CTIC) Stock Price, News & Analysis → Your bank account could be compromised (From Weiss Ratings) (Ad) Free CTIC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.09▼$9.0950-Day Range$8.91▼$9.1052-Week Range$4.01▼$9.10VolumeN/AAverage Volume4.50 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get CTI BioPharma alerts: Email Address Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. About CTI BioPharma Stock (NASDAQ:CTIC)CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Read More Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. CTIC Stock News HeadlinesMay 8, 2024 | uk.finance.yahoo.comQ1 2024 Veracyte Inc Earnings CallFebruary 22, 2024 | investing.comConnect Biopharma Holdings Ltd (CNTB)June 30, 2024 | InvestorPlace (Ad)Where AI is REALLY Going NextBuying Nvidia was a good idea – twenty years ago when I first recommended it (for up to 37,000% gains). But chipmakers are the FIRST GENERATION of AI. And just like the dot-com era… That’s NOT where the big money will be made.December 16, 2023 | morningstar.comTheravance Biopharma Inc TBPHOctober 23, 2023 | uk.investing.comCTI Engineering Co Ltd (9621)August 23, 2023 | stockhouse.comSEC Charges Former Attorney at U.S.-Based Global Law Firm with Insider TradingJune 27, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi completes acquisition of CTI BioPharma Corp.June 26, 2023 | finance.yahoo.comSobi completes acquisition of CTI BioPharma Corp.June 30, 2024 | InvestorPlace (Ad)Where AI is REALLY Going NextBuying Nvidia was a good idea – twenty years ago when I first recommended it (for up to 37,000% gains). But chipmakers are the FIRST GENERATION of AI. And just like the dot-com era… That’s NOT where the big money will be made.June 7, 2023 | markets.businessinsider.comCTI BioPharma (CTIC) was upgraded to a Hold Rating at Stifel NicolausMay 30, 2023 | markets.businessinsider.comStifel Nicolaus upgrades CTI BioPharma (CTIC) to a HoldMay 25, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 25, 2023 | finance.yahoo.comSobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 24, 2023 | msn.comJMP Securities Maintains CTI BioPharma (CTIC) Market Perform RecommendationMay 24, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)May 16, 2023 | msn.comCTI BioPharma: $1.7bn M&A With 85% Premium, Expect The Deal To Go ThroughMay 16, 2023 | msn.comSVB Leerink Downgrades CTI BioPharma (CTIC)May 16, 2023 | markets.businessinsider.comSVB Securities downgrades CTI BioPharma (CTIC) to a HoldMay 16, 2023 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates CTI BioPharma Corp.May 15, 2023 | msn.comStifel Downgrades CTI BioPharma (CTIC)May 15, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for CTI BioPharmaMay 12, 2023 | msn.comNeedham Downgrades CTI BioPharma (CTIC)May 12, 2023 | msn.comUnusual Call Option Trade in CTI BioPharma (CTIC) Worth $312.39KMay 11, 2023 | reuters.comSweden's SOBI offers $1.7 bln to buy CTI BioPharmaMay 11, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating CTI BioPharma Corp. BuyoutMay 11, 2023 | markets.businessinsider.comCTI BioPharma (CTIC) was downgraded to a Hold Rating at JMP SecuritiesMay 10, 2023 | msn.comCTI BioPharma shares soar 83% after Swedish Orphan Biovitrum announces $1.7 billion deal for the biotechSee More Headlines Receive CTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2023Today6/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTIC Previous SymbolNASDAQ:CTICD CUSIPN/A CIK891293 Webwww.ctibiopharma.com Phone(206) 282-7100Fax206-284-6206Employees127Year Founded1992Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,990,000.00 Net Margins-91.38% Pretax Margin-91.38% Return on EquityN/A Return on Assets-55.82% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.26 Sales & Book Value Annual Sales$53 million Price / Sales22.62 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-64.93Miscellaneous Outstanding Shares131,880,000Free Float121,844,000Market Cap$1.20 billion OptionableOptionable Beta0.83 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Adam R. Craig M.B.A. (Age 57)M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director Comp: $1.09MMr. David H. Kirske (Age 69)Exec. VP, CFO & Sec. Comp: $590.41kMr. James K. Fong (Age 61)Exec. VP & Chief Commercial Officer Comp: $597.3kMr. Ed BellSr. Director of Investor RelationsMr. Bruce K. Bennett Jr. (Age 71)Sr. VP Global Pharmaceutical Operations Mr. John P. VolponeExec. VP & Chief of StaffDr. Jennifer A. SmithSr. VP of BiometricsMore ExecutivesKey CompetitorsAltimmuneNASDAQ:ALTFulcrum TherapeuticsNASDAQ:FULCKamadaNASDAQ:KMDAParatek PharmaceuticalsNASDAQ:PRTKHookipa PharmaNASDAQ:HOOKView All Competitors CTIC Stock Analysis - Frequently Asked Questions How were CTI BioPharma's earnings last quarter? CTI BioPharma Corp. (NASDAQ:CTIC) announced its quarterly earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analysts' expectations of $24.88 million. During the same period in the previous year, the firm earned ($0.38) earnings per share. When did CTI BioPharma's stock split? Shares of CTI BioPharma reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is James A. Bianco's approval rating as CTI BioPharma's CEO? 8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of CTI BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN). This page (NASDAQ:CTIC) was last updated on 6/30/2024 by MarketBeat.com Staff From Our PartnersElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredYour bank account could be compromisedLegendary financial forecaster, Dr. Martin Weiss has recently uncovered the government's chilling new program ...Weiss Ratings | SponsoredNext-Gen AI is Creating Millionaires Right NowI predict massive unemployment is coming. 800 million could lose their jobs, according to a McKinsey study,...InvestorPlace | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CTI BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share CTI BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.